India Ink: India Rejects Bayer Plea Against Cheap Cancer Drug
Linkedin

India Ink: India Rejects Bayer Plea Against Cheap Cancer Drug

New Delhi : India | Mar 05, 2013 at 10:02 PM PST
Source: Newyork Times
XX XX
Views: Pending
 
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines to the poor. FULL ARTICLE AT Newyork Times
1 of 1
Under the ruling, Bayer will get a six percent royalty on sales of the drug
Under the ruling, Bayer will get a six percent royalty on sales of the drug
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

News Stories

 
  • Bayer to move HC to protect patent drug

      India Abroad
    A day after the Intellectual Property Appellate Board reinforced the first compulsory licence granted in India on an anti-cancer medicine, German multinational Bayer said it would approach the Mumbai High Court with a petition. Bayer is committed to...
  • Patent drug pricing to distract from licences

      India Abroad
    T he latest recommendations by a government panel on the proposed patented drug pricing policy are seen as a threat to compulsory licensing, which has just begun in India [ Images ]. The panel of representatives from various ministries and chaired by...

Images

 >
 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.